Sunshine Guojian Pharmaceutical Shanghai Co Ltd (688336)

Currency in CNY
51.65
+0.05(+0.10%)
Closed·

688336 Financial Summary

Key Ratios

P/E Ratio23.37
Price/Book2.95
Debt / Equity0.89%
Return on Equity13.25%
Dividend Yield0.24%
EBITDA334.08M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2014
31/12
2015
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
* In Millions of CNY (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 1.16%
Dividend Yield
0.24%
Industry Median 1.51%
Annualised payout
0.12
Paid annually
5-Years Growth
-
Growth Streak

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 48.64
(-5.83% Downside)

Earnings

Latest Release
May 30, 2025
EPS / Forecast
0.17 / --
Revenue / Forecast
311.12M / --
EPS Revisions
Last 90 days

FAQ

What were Sunshine Guojian Pharmaceutical Shanghai Co's earnings for the latest quarter?

The Sunshine Guojian Pharmaceutical Shanghai Co EPS (TTM) is 1.16. Sunshine Guojian Pharmaceutical Shanghai Co reported sales of 311.12, net income of 102.96, and EPS of 0.17 for the latest quarter.

What was Sunshine Guojian Pharmaceutical Shanghai Co's net income for the latest quarter?

Sunshine Guojian Pharmaceutical Shanghai Co's net income for the latest quarter was 102.96.

How did Sunshine Guojian Pharmaceutical Shanghai Co's performance compare year-over-year in the latest quarter?

The company's revenue moved from 254.16 in the previous quarter to 311.12 in the latest quarter, and net income moved from 471.53 to 102.96 compared to the previous quarter.

What is Sunshine Guojian Pharmaceutical Shanghai Co's net profit margin on a TTM basis?

Sunshine Guojian Pharmaceutical Shanghai Co's trailing twelve months (TTM) net profit margin is 59.03%.

How does Sunshine Guojian Pharmaceutical Shanghai Co's debt to equity ratio compare to industry standards?

Sunshine Guojian Pharmaceutical Shanghai Co's total debt-to-equity ratio is 0.89%.

What is Sunshine Guojian Pharmaceutical Shanghai Co's return on investment on a TTM basis?

Sunshine Guojian Pharmaceutical Shanghai Co's trailing twelve months (TTM) return on investment (ROI) is 13.25%.

Did Sunshine Guojian Pharmaceutical Shanghai Co gain or lose cash last quarter?

In the latest quarter, Sunshine Guojian Pharmaceutical Shanghai Co's net change in cash was 91.18 million.

What were Sunshine Guojian Pharmaceutical Shanghai Co's total assets and liabilities in the latest quarter?

As of the latest quarter, Sunshine Guojian Pharmaceutical Shanghai Co reported total assets of 6,041.86 million and total liabilities of 297.46 million.

How has Sunshine Guojian Pharmaceutical Shanghai Co's total revenue grown this year?

Sunshine Guojian Pharmaceutical Shanghai Co's total revenue was 254.16 in the previous quarter and 311.12 in the latest quarter.

What is Sunshine Guojian Pharmaceutical Shanghai Co's gross margin on a TTM basis?

Sunshine Guojian Pharmaceutical Shanghai Co's trailing twelve months (TTM) gross margin is 74.27%.

What was Sunshine Guojian Pharmaceutical Shanghai Co's revenue per share for the latest quarter?

Sunshine Guojian Pharmaceutical Shanghai Co's revenue per share for the latest quarter was 6.96.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.